A Population Perspective on Prevention of Dementia by Eggink, E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/209011
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
Journal of
Clinical Medicine
Review
A Population Perspective on Prevention of Dementia
Esmé Eggink 1,*, Eric P. Moll van Charante 1 , Willem A. van Gool 2 and Edo Richard 2,3
1 Department of General Practice, Amsterdam University Medical Center, University of Amsterdam,
Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands; e.p.mollvancharante@amc.uva.nl
2 Department of Neurology, Amsterdam University Medical Center, University of Amsterdam,
Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands; w.a.vangool@amc.uva.nl (W.A.v.G.);
e.richard@amc.uva.nl (E.R.)
3 Department of Neurology, Donders Institute for Brain, Behaviour and Cognition, Radboud University
Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
* Correspondence: e.eggink@amc.uva.nl
Received: 15 May 2019; Accepted: 9 June 2019; Published: 12 June 2019


Abstract: The global number of people living with dementia is expected to increase to 130 million in
2050. Based on extensive evidence from observational studies, it is estimated that about 30% of dementia
cases may be attributable to potentially modifiable risk factors. This suggests that interventions targeting
these factors could perhaps delay or prevent the onset of dementia. Since the vast majority of people
with dementia live in low- and middle-income countries, such interventions should preferably be easy
and affordable to implement across a wide range of health care systems. However, to date, results
from dementia prevention trials do not provide convincing evidence that treatment of these risk factors
reduces the risk of dementia. The current paper aims to give an overview of available evidence for the
potential for dementia prevention. In particular, we discuss methodological issues that might complicate
the development of effective prevention interventions and explore the opportunities and challenges
for future dementia prevention research. Currently, several ongoing and planned trials are testing the
effect of multi-domain interventions on dementia risk in high-risk populations. It is desirable that future
dementia strategies also target the wider population, through interventions on the individual, community,
and population level, in order to constrain the growing prevalence of dementia worldwide.
Keywords: dementia prevention; Alzheimer’s disease; vascular risk factors; multi-domain
interventions; public health
1. Changing Perspectives on Late-Life Dementia
The clinical picture of dementia has been recognized for centuries, but throughout time the theories
on its causes have varied widely. Dementia received specific attention in 1907, when Alois Alzheimer
wrote his famous case report ‘’About a peculiar disease of the cerebral cortex” [1]. His findings of
plaques and tangles in the brain of a 51-year old patient with progressive cognitive problems were
included in a leading psychiatry textbook by Emil Kraepelin, and the condition was referred to with
the term ‘’Alzheimer’s disease” (AD) [2]. From then on, AD was considered to be a rare condition,
causing dementia through plaques and tangles in relatively young people. Cognitive decline in the
last decades of life, at the time referred to as senile dementia, was considered to be attributable to
atherosclerosis, and stroke and was thought of as a distinct condition [3].
From the early seventies onwards, perceptions of the pathogenesis of senile dementia shifted from
vascular mechanisms to AD pathology, based on the discovery of extensive amounts of extracellular
amyloid depositions (plaques) and intracellular depositions of hyperphosphorylated tau-protein (tangles)
in the brains of older people with dementia [4]. Consequently, the sharp distinction between presenile and
senile dementia faded. In the early nineties, it was discovered that the specific e4 allele of Apolipoprotein
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E (APOEε4) was associated with both early- and late-onset dementia [5,6], supporting the hypothesis
that Alzheimer’s disease was the predominant cause of both early- and late-onset dementia. At this time,
vascular dementia was still considered a separate, less frequent cause of dementia.
The role of vascular pathology in the development of late-life dementia regained interest in the
late nineties, when several epidemiologic and radiologic studies reported a strong relationship of
cardiovascular risk factors and disease with impaired cognitive functioning [7,8]. These findings were
supported by neuropathological findings. Examination of the brains of 102 elderly nuns suggested a
strong interaction effect on cognitive functioning between the presence of AD pathology and lacunar
strokes [9]. A large autopsy study in a population-based cohort in the United Kingdom, with a
median age of 85 at death, showed that most dementia patients had a mixture of cerebrovascular and
AD pathology, whereas subjects without dementia often had a considerable level of pathologies as
well, or no pathologies at all [10]. Since then, numerous epidemiologic studies have investigated the
relationship between vascular risk factors or vascular disease, and stroke development, and late life
dementia [11–13]. Based on several more recent studies, it is perceived that the presence and mutual
interaction of genetic factors, such as carrying the APOEε4 allele, and vascular factors are involved
in the development of multiple brain pathologies, including amyloid plaques, tangles containing
hyperphosphorylated tau, and different vascular lesions [14–16]. These brain pathologies all increase
the likelihood to develop mild cognitive impairment (MCI) and dementia [17], but they are not
sufficient to fully explain either onset, course, or specific clinical symptoms.
2. Exploring the Window of Opportunity for Dementia Prevention
The concept of dementia caused by multifaceted brain disease implies a wide range of possible
strategies for dementia prevention and treatment. The need for such strategies is emphasized by the
large number of people living with dementia worldwide, which is expected to rise from 47 million
in 2015 to over 130 million in 2050, largely due to the increasing life expectancy [18]. It is estimated
that 90% of dementia patients are older than 75 years, and 75% are older than 80 years of age [19].
Strategies to prevent dementia among people without the disease could perhaps delay its onset and
reduce the prevalence of dementia [20]. Since it is expected that by 2050 68% of all people with
dementia live in low- and middle-income countries (LMIC) [18], such strategies should ideally be easy
and inexpensive to implement on a large scale across a wide variety of health care systems.
Observational studies suggest a number of modifiable factors that are associated with dementia
risk and could serve as a target for prevention. Elevated blood pressure, body mass index (BMI),
elevated total cholesterol levels [21–26], diabetes mellitus [27], current smoking [28], depression [29],
physical inactivity [30], cognitive inactivity [31], poor diet [32], and low educational attainment [33]
are well-established factors that are independently associated with an increased risk of dementia.
Even small improvements of the modifiable dementia risk factors on the individual level have the
potential to lead to a substantial reduction of dementia cases at the population level, due to the high
global prevalence of these risk factors [34]. By calculating population-attributable risks for seven
well-established dementia risk factors (diabetes mellitus, midlife hypertension, midlife obesity, physical
inactivity, depression, smoking, and low educational attainment), and taking inter-relatedness into
account, it was estimated that 30% of all dementia cases worldwide can be attributed to these potentially
modifiable risk factors [35], with low educational attainment, smoking, and physical inactivity carrying
the strongest risk. This suggests a large window of opportunity for dementia prevention.
The high prevalence of these modifiable factors raises the question of whether population-based
prevention strategies could reduce the prevalence of dementia. Over the years, many community programs
have been designed to reduce cardiovascular disease (CVD) risk. Controlled before–after studies have
shown that, in general, these programs can be effective at improving cardiovascular risk factors and,
in some cases, reducing incident CVD and mortality [36]. Although risk factors are largely similar for CVD
and dementia, no comparable studies have been performed to study the effect of community prevention
programs on cognitive functioning or dementia. However, five large studies have compared dementia
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occurrence between two time points in well-defined geographical areas. Four of five studies showed a slight
reduction of dementia prevalence, which could potentially be attributed to population-level investments,
including improved education and better prevention and treatment of vascular conditions [37].
3. Dementia Prevention Trials
In the last two decades, several intervention studies have been performed to test the hypothesis that
dementia can be delayed or prevented by improving individual risk factors or the overall dementia risk
profile in people free from cognitive impairment at baseline. We distinguish single-domain interventions,
targeting a single risk factor, and multi-domain interventions, targeting multiple dementia risk factors
simultaneously. Below, we will discuss these studies with dementia as a primary or secondary outcome.
3.1. Single-Domain Interventions
Although the list of potential interventions is very long [38], we will restrict our overview to
the interventions for which most robust evidence from clinical trials and meta-analyses is available.
As such, we do not intend to be exhaustive here.
Treatment of hypertension may reduce the risk of dementia via blood pressure lowering
mechanisms, but also through other, perhaps antihypertensive class-specific, effects [21,39–41].
Results of hypertension trials have been encouraging, but are still inconclusive. A meta-analysis of four
placebo-controlled trials of antihypertensive treatment with incident dementia as a primary outcome
showed a combined risk ratio of 0.87 (95% CI 0.76 to 1.00; N = 16,595 individuals; n = 786 dementia
cases), favoring treatment [42]. A more recent meta-analysis included nine blood pressure-lowering
trials, including two lifestyle interventions, with a median follow-up of 3.9 years. The pooled risk
ratio for incident dementia was 0.93 (95% CI 0.84 to 1.02; N = 57,682; n = 2131 dementia cases) [43].
The recently published Systolic Blood Pressure Intervention Trial: Memory and Cognition in Decreased
Hypertension sub-study (SPRINT-MIND) assessed whether intensive blood pressure treatment with
any agent, aiming for levels lower than 120 mmHg, could reduce incident dementia compared with
standard blood pressure control, aiming for levels lower than 140 mmHg, in over 9000 patients (50+)
with hypertension. The trial was ended prematurely because of beneficial effects on cardiovascular
events and all-cause mortality in the intervention group. Pre-planned secondary analyses showed no
significant effect on probable dementia (HR 0.83; CI 0.67 to 1.04; N = 8563; n = 325 dementia cases),
but a significant reduction of incident MCI (HR 0.81; CI 0.69 to 0.95; N = 8563; n = 640 probable MCI
cases) after a median intervention period of 3.3 years and a median follow-up period of 5.1 years [44].
Taken together, despite promising results from observational studies [21], these two meta-analyses and
recent RCT failed to provide convincing evidence that dementia can be delayed or prevented with
blood pressure treatment, but point estimates consistently suggest a potential preventive effect.
Type 2 diabetes mellitus (T2DM) may increase dementia risk through different mechanisms including
cerebrovascular damage, insulin resistance, and mitochondrial dysfunction [45,46]. A recent systematic
review identified seven randomized controlled trials to assess the effects of different T2DM treatment
strategies on cognitive function and incident dementia [47]. Three studies were included in the efficacy
analyses and used cognitive function or incident dementia as outcome measure. All three studies were at
unclear risk of bias. Two of these studies compared intensive glycemic control versus standard glycemic
control [48,49]. There was no significant difference between the two groups with regard to the number
of participants who declined by at least 3 points on the mini-mental state examination (MMSE) over five
years (RR 0.98; CI 0.88 to 1.08; N = 11,140 individuals; 1 study), incident dementia (RR 1.27; CI 0.87 to
1.85; N = 11,140 individuals; n = 109 dementia cases; 1 study) [49], or MMSE score after 40 months (MD
−0.01; CI −0.18 to 0.16; N = 2794 individuals; 1 study) [48]. The third study compared glibenclamide with
repaglinide. After 12 months, a small advantage of glibenclamide on MMSE score was found (MD −0.90;
CI −1.68 to −0.12; N = 156 individuals; 1 study) [50].
Despite observational evidence [23,24], to date no trials have shown beneficial effects of
cholesterol-lowering treatment on dementia risk. A systematic review identified two RCTs that
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compared the effect of a statin versus placebo on cognitive decline and incident dementia among
individuals with increased cardiovascular risk. Both studies had a low risk of bias. No difference
was found with regard to incident dementia (OR 1.00; CI 0.61 to 1.65; N = 20,536; n = 62 dementia
cases; 1 study) between simvastatin and placebo. No effect of simvastatin or pravastatin was found
on cognitive function, assessed by five different cognitive tests [51]. According to current guidelines,
a very high percentage of participants between 40 and 75 years old are eligible for statin prescription,
with the aim to prevent cardiovascular disease [52]. Although the prevention of stroke can be expected
to lower the risk of dementia, there is no direct evidence for this effect so far.
Physical activity is thought to decrease dementia risk through multiple mechanisms, including
increased neurogenesis, angiogenesis, and synaptic plasticity and anti-inflammatory effects [53].
Moreover, physical activity can have beneficial effects on other factors that are associated with
dementia risk, including obesity, dyslipidemia, and high blood pressure. A recent systematic review
investigated 32 trials with a follow-up of more than 6 months, to assess the effectiveness of physical
activity interventions on cognitive function among adults without a diagnosis of cognitive impairment.
Included studies targeting only physical activity involved aerobic training (six studies, 531 individuals),
resistance training (three trials, 315 individuals), and tai chi (one trial, 93 individuals). Evidence from
these trials was insufficient to draw any conclusion about a beneficial effect on cognitive function [54].
Because of the beneficial effects of physical activity on obesity and the risk of CVD, public health
campaigns and public health initiatives to facilitate physical activity are widely applied. To date,
whether this will reduce the risk of dementia remains uncertain.
3.2. Multi-Domain Interventions
Exposure to a combination of modifiable dementia risk factors may have a synergistic effect on
risk of cognitive decline and dementia [55,56]. Therefore, multi-domain interventions, targeting more
than one risk factor, may be a more appropriate approach to study dementia prevention. In the past
decade, several multi-domain trials have been performed, testing varying interventions across a wide
range of sample sizes and follow-up times. We will discuss the main multi-domain intervention
studies in terms of sample size and follow-up time with dementia, MCI, or cognitive decline as primary
end-point (Table 1).
Table 1. Multi-domain dementia prevention trials.
preDIVA FINGER MAPT
Sample size 3526 1260 1680
Age range 70–78 60–77 70+
Main inclusion criteria Not demented b
Dementia risk score ≥6 a
Cognitive performance at
mean or slightly lower level
Not demented b
Memory complaints or limitations
in daily living or slow gait speed
Intervention Nurse-led intensive vascularcare
Diet advice, exercise,
cognitive training and
vascular care
Cognitive training, advice on
physical activity and nutrition,
and vascular care +/− omega
3 polyunsaturated fatty acids
Intervention period 6–8 years 2 years 3 years
Follow-up period 6–8 years 2 years 3 years
Primary outcome Dementia, disability d Cognitive function c
Composite z-score of 4 cognitive
tests e
Main secondary outcomes
Cardiovascular disease,
vascular factors, cognitive
decline, depression
Vascular and lifestyle factors,
depressive symptoms,
disability
Physical performance, depression
FINGER: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability; MAPT: Multidomain
Alzheimer Prevention Study; preDIVA: prevention of Dementia by Intensive Vascular Care. a assessed with
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) risk score; b defined as no clinical diagnosis and a
Mini-Mental State Examination >23; c assessed with the neuropsychological test battery (NTB); d assessed with
the AMC Linear Disability Score; e items from the Free and Cued Selective Reminding test, Mini-Mental State
Examination, Digit Symbol Substitution Test, and Category Naming Test.
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The Dutch prevention of Dementia by Intensive Vascular Care (preDIVA) [57] cluster-randomized
trial compared the effect of a 6-year, intensive, nurse-led multi-domain cardiovascular care intervention
with usual care on the cumulative incidence of dementia and disability. 116 General practices were
randomly assigned to one of the conditions. 3526 individuals without dementia, aged 70–78 years,
participated. After a median follow-up of 6.7 years, primary outcome data were obtained in more than
98% of the participants. No significant effect was found of the intensive cardiovascular care on incident
dementia (HR 0.92; CI 0.71 to 1.19; N = 3454 individuals; n = 233 dementia cases) and disability.
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
(FINGER) [58] compared the effect of a multi-domain intervention, including nutritional guidance,
physical activity, cognitive training, and monitoring of modifiable dementia risk factors, with general
health advice (control group) on cognitive function, assessed with an extensive neuropsychological test
battery (NTB). 1260 Individuals without dementia, aged 60–77 years, with an increased dementia risk
in terms of 6 or more points on the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk
score, were randomly assigned to either of the treatment arms. After two years, the intervention group
showed a slightly larger improvement on the standardized NTB compared with the control group
(between-group difference in change score per year 0.022; CI 0.002 to 0.042; N = 1190 individuals).
The French Multidomain Alzheimer Preventive Trial (MAPT) [59] studied the effects of omega
3 polyunsaturated fatty acids and the effect of a multi-domain intervention, consisting of group sessions
targeting cognitive training, physical activity, and nutrition on cognitive function. Participants were
eligible when they were 70 years or older and either had subjective memory complaints, limitations in
one instrumental activity of daily living, or slow walking speed. 1680 Participants were randomly
assigned to one of four groups: the multi-domain intervention combined with omega 3 polyunsaturated
fatty acids, the multi-domain intervention with placebo, and omega 3 polyunsaturated fatty acids
with no other intervention or placebo alone. After three years, there were no significant differences in
cognitive function, assessed with a composite score of four cognitive tests, between any of the treatment
groups and the placebo alone group: between-group differences were 0.093 (95% CI 0.001 to 0.184; N =
1525 individuals) for combined intervention, 0.079 (95% CI−0.012 to 0.170; N = 1525 individuals) for the
multi-domain intervention plus placebo group, and 0.011 (95% CI −0.081 to 0.103; N = 1525 individuals)
for the omega 3 polyunsaturated fatty acids group.
4. Explaining the Gap between Observational and Interventional Studies
A substantial gap exists between the results from many observational studies, suggesting optimism,
and the rather sobering results from dementia prevention trials. Hence, it could be that vascular
factors have an association, rather than a causal relationship, with dementia risk. However, most of
Hill’s criteria for causation, such as consistency and plausibility [60], are met. Although the current
evidence does not support a protective effect of preventive interventions for dementia, particularly for
hypertension, there is a rather consistent signal in the direction of a preventive effect. Moreover, it is
conceivable that methodological issues, which have been associated with the design of dementia
prevention trials [61–63], lead to type II errors, masking “true” effects of multi-domain interventions,
and causing apparent inconsistency with observational evidence.
4.1. Age of the Target Population and J-Shaped Curves
An important issue when designing a dementia prevention trial is the optimal age range of the
target population. A target population that is too young would require infeasible follow-up periods or
sample sizes, due to the low incidence of dementia in younger age. Conversely, a target population
that is too old would probably lead to decreased efficacy of the intervention, because the relationship
between some risk factors and dementia becomes more complex with age [63]. The association between
blood pressure during late-life and dementia is suggested to follow a U- or J-shaped curve, with both
high and low values imposing increased dementia risk [64]. This is consistent with ample research
on the relationship between blood pressure and cardiovascular disease [65]. With regard to BMI,
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a similar J-shaped relation with dementia risk is suggested in late-life, with elevated BMI levels being
associated with lower, and being underweight with increased, dementia risk [66], suggesting a similar
type of J-shaped curve as with blood pressure. Likewise, high total serum cholesterol concentrations in
late-life have been associated with decreased dementia risk [24,67]. It is unclear when the directions of
these associations change. Nevertheless, it is conceivable that the target populations from the three
multi-domain interventions described above, with age-ranges 60–77, 70+, and 70–78 years, respectively,
were too old to benefit from the interventions. These complex relationships pose a major challenge for
future dementia prevention trials. Clearly, one size does not fit all, but with regard to age it is currently
unclear what the optimal target values for blood pressure, BMI, and cholesterol might be.
4.2. Risk Profile of the Target Population
The level of quality and accessibility of standard preventive care that is available for the target
population affects the degree of contrast a trial may yield. Subgroup analyses of the preDIVA study show
the strongest effects of the intervention in participants with untreated hypertension and in participants
without history of cardiovascular disease [57]. It could well be that an effect of the intervention was
not found in the three multi-domain intervention trials, because high-quality cardiovascular risk
management was already available for both intervention and control participants. As such, future
studies may need to target populations at high risk who lack access to high-quality preventive health
care. Policymakers and health organisations alike may need to actively target those persons that are
typically not represented in clinical trials, but are at highest risk.
4.3. Hawthorne and Treatment Effects in the Control Condition
Another challenge is the observed improvement on primary and secondary outcomes of the
control group in some multi-domain intervention studies [57,58]. This is illustrated by the decrease in
blood pressure in both study arms of the preDIVA trial. The mean difference in systolic blood pressure
between baseline and follow-up was 8.3 mmHg in the intervention group and 4.6 mmHg in the control
group, suggesting initiation of treatment by a general practitioner or specialist or changes in lifestyle
behaviour by the participant following the baseline measurements. Additionally, changed behaviour of
participants or healthcare professionals as a reaction to the awareness of the study (Hawthorne effect)
is likely to play a role [68]. Both mechanisms could mask the “true” contrast between the intervention
and control condition, leading to type II errors.
4.4. Competing Risk of Death
Age is the most important risk factor for dementia. Starting at the age of 60, the incidence
of dementia doubles with every 6.3 years increase in age [18]. It is likely that, due to shared risk
factors, dementia prevention trials have beneficial effects on cardiovascular endpoints, and, as a
consequence, on mortality. Therefore, effective multifactorial interventions could paradoxically
increase dementia incidence rates when death is delayed. If not taken into account, this could lead to
serious underestimation of the effectiveness of dementia prevention interventions.
5. Future Directions
5.1. Strategies to Deal with Limited Statistical Power
When designing dementia prevention trials, sufficiently large sample sizes and/or long follow-up
periods are paramount to reach statistical power, due to the time lag between the optimal timing of the
intervention and dementia onset. Hence, given these preconditions, funding dementia prevention
trials will remain a daunting challenge.
One potential approach towards longer follow-up is open label extension of studies, as was done in
the Syst-Eur trial [13]. However, selective attrition will be a complicating factor for such observational
extensions. Another strategy to overcome lack of power is to collaborate with other (international)
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research groups, enabling the design of multi-national trials and pooling of data of previous trials
where possible and appropriate. An example is the European Dementia Prevention Initiative (EDPI)
consortium, a collaboration of five European institutes, including the three research groups involved in
the FINGER, MAPT, and preDIVA trials, respectively [69]. A third strategy could involve selection of a
primary outcome that is likely to emerge earlier in life than dementia onset. Examples are cognitive
impairment, existing dementia risk scores, or biomarkers presumed to reflect biological processes
eventually leading to dementia. However, the uncertain association between biomarkers and cognition
renders this a suboptimal primary outcome with regard to clinical relevance. A fourth solution could
be to exclusively target individuals with an increased dementia risk who are still free from cognitive
impairments. Numerous strategies exist to estimate dementia risk, including the use of biomarkers,
imaging [70], family history [71], and dementia risk scores [72,73]. Obviously, from a population
perspective, the use of (invasive) biomarkers is not feasible, certainly not in LMIC, but simple and
readily available risk markers such as a positive family history or the presence of multiple dementia
risk factors can be applied on a large scale at low cost. Some researchers have also used signs of
cognitive decline to indicate high dementia risk. However, the latter approach is accompanied by a
relatively high risk of including individuals with an early stage of dementia, in whom the intervention
is less likely to be effective [74]. A fifth approach could be to target populations with poor access to
preventive healthcare quality, such as in LMIC. These populations could be a promising target for
lifestyle interventions, since the incidence of dementia is relatively high and the peak incidence is at
younger age than in high-income countries (HIC) [18]. Moreover, the prevalence of dementia risk
factors in these countries is higher than in HIC [75].
5.2. Ongoing and Planned Multi-Domain Dementia Prevention Trials
For successful implementation in LMIC, dementia prevention interventions should ideally be
easily available, accessible, and affordable. These criteria are often met by web-based interventions,
such as electronic health (eHealth) and mobile health (mHealth), especially because the majority
of the world population uses internet these days and in countries with limited internet access it is
increasing rapidly [76]. Four currently ongoing or planned multi-domain interventions will be testing
the effectiveness of such digital dementia prevention interventions (Table 2).
The ongoing multi-national Healthy Aging Through Internet Counselling in the Elderly (HATICE)
trial, performed by the EDPI consortium, is comparing a coach-supported, interactive internet platform,
stimulating self-management of cardiovascular risk factors, with a sham platform without interactive
features, for 18 months. The study population consists of approximately 2724 individuals, aged 65 years
or older, and with an increased cardiovascular risk. The primary endpoint is a composite cardiovascular
risk score, including systolic blood pressure, low-density-lipoprotein, and BMI. Cognitive function is a
secondary outcome [77].
An ongoing cluster-randomized trial in Thailand with 3600 participants is comparing a three-year
digital, coach-supported lifestyle modification intervention on four domains (diet, physical activity,
alcohol drinking, and smoking) with care as usual. Participants are eligible when they are between
45 and 75 years of age and do not have a diagnosis of dementia, chronic kidney disease, diabetes,
chronic obstructive pulmonary disease, cancer, or CVD. The primary outcome, measured after ten
years, is incident dementia. Cognitive function, assessed with the MMSE, is one of the secondary
outcomes [78].
The Maintain Your Brain (MYB) trial is comparing a digital platform with interactive modules
on physical activity, diet, mental health, and cognitive training with a digital platform containing
static information about dementia risk factors. The study population will consist of approximately
8500 individuals, recruited through an existing Australian cohort of non-demented community
dwelling individuals aged between 55 and 77 years. The primary outcome, measured after three years,
is cognitive change on a composite score of cognitive functioning. Secondary outcomes are incident
dementia and change in dementia risk [79].
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The planned Prevention Of Dementia Through Mobile Phone Applications (PRODEMOS) trial,
initiated by the EDPI consortium, takes place in the United Kingdom (UK) and in Beijing, China [80].
A total of 2400 individuals, aged 55–75 years, with an increased dementia risk profile, and of low
socioeconomic status in the UK, are randomized between a coach supported, interactive smartphone
application, stimulating self-management of dementia risk factors; and a sham application without
interactive features. The primary endpoint, measured after 18 months, is the CAIDE dementia
risk score.
World Wide Fingers is an interdisciplinary network that arose from the FINGER trial.
The multi-domain lifestyle intervention showed a modest beneficial effect on cognitive function
after two years in a Finnish geriatric population. The same intervention is going to be tested in the
United States, in rural China, in Singapore, and in several European countries [81].
Table 2. Planned and ongoing multi-domain dementia prevention trials.
HATICE
Impact of Lifestyle
Modification on
Prevention of Dementia
MYB PRODEMOS
Start of recruitment March 2015 March 2016 May 2018 January 2020
Sample size 2724 3600 8500 2400
Recruiting
countries
The Netherlands,
Finland, France Thailand Australia
United Kingdom,
China
Age range 65+ 45–75 55–77 55–75
Main inclusion
criteria
Not demented a,
≥2 cardiovascular
risk factors
Thai nationality,
no diagnosis of
dementia, diabetes,
COPD, cancer, or CVD
No diagnosis of
dementia or severe
depression
Not demented a,
≥2 dementia risk
factors
Intervention
Coach-supported
Internet platform for
self-management of
cardiovascular risk
factors
Coach-supported
computer program on
diet, physical activity,
alcohol drinking,
and smoking
Digital modules on
physical activity,
nutrition, peace of
mind, and brain
training
Coach-supported
smartphone app for
self-management of
dementia risk factors
Intervention period 1.5 years 3 years 3 years 1.5 years
Follow-up period 1.5 years 10 years 3 years 1.5 years
Primary outcome
Composite z-score of
SBP, LDL cholesterol,
and BMI
Incident dementia
Global cognition
composite domain
score b
CAIDE score,
implementation
outcomes
Main secondary
outcomes
Individual factors
from composite
score, incident CVD
Incident T2DM, CVD,
cancer, COPD, mortality
Incident dementia,
dementia risk
Individual components
of CAIDE score,
disability,
cost-effectiveness
BMI: body mass index; CAIDE: Cardiovascular Risk Factors, Aging, and Dementia risk score; COPD: chronic
obstructive pulmonary disease; CVD: cardiovascular disease; HATICE: Healthy Aging Through Internet Counselling
in the Elderly; Impact of Lifestyle Modification on Prevention of Dementia: Impact of Lifestyle Modification on
Prevention of Dementia, Chronic Kidney Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancers,
and Cardiovascular Disease in a Thai General Population: Cluster Randomized Controlled Trial; LDL: low-density
lipoprotein; MYB: Maintain Your Brain; PRODEMOS: Prevention Of Dementia Through Mobile Phone Applications;
SBP: systolic blood pressure; T2DM: type 2 diabetes mellitus. a defined as Mini-Mental State Examination >23;
b Maintain Your Brain Battery.
5.3. Population-Based Approaches
Most of the ongoing trials are testing individual interventions in specific high-risk populations.
However, the majority of dementia cases occur in individuals with low or intermediate risk [82].
It is therefore desirable that future dementia prevention strategies also target the wider population.
Interventions targeting (a subgroup of) the population as a whole require different strategies. In addition
to the individual level, primary prevention can be delivered at the community or the population
level. Public health interventions that target common risk factors, such as discouraging smoking
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and encouraging a healthier lifestyle, can be implemented at several levels, and may include media
campaigns, legislative changes, and preventive measures in working spaces and the community.
Evaluating the effects of such interventions is complex, and may require different approaches than
the classical parallel group randomised controlled trial. In addition to alternative methodologies to
evaluate effectiveness, measures related to implementation will have to be taken into account, and such
studies may require alternative large-scale governmental funding. Since risk factors for dementia
largely overlap with risk factors for CVD, implementation in existing healthcare would probably benefit
from an integrated approach, targeting dementia, CVD, and other non-communicable diseases [83].
6. Conclusions
Although results from observational studies suggest optimism, to date, results from
dementia-prevention trials do not provide convincing evidence that treatment of these risk factors
reduces the risk of dementia. However, some interventions, especially in intensive hypertension
management, appear promising in the reduction of dementia risk and cognitive decline. Taking into
account that the majority of dementia cases occur in LMIC, interventions should be easy and affordable
to implement. Currently, several ongoing trials are testing the effectiveness of eHealth and mHealth
interventions in high-risk individuals. Further implementation research on broadly available preventive
interventions in the general population is warranted, to achieve global impact on dementia prevalence.
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